Recalmin D3 Oral Solution Sugar Free
Recalmin D3 Oral Solution Sugar Free is a high-strength Vitamin D3 supplement manufactured by Tirupati Medicare and marketed by Leeford Healthcare. Each 5 ml dose contains Cholecalciferol IP 60,000 IU in a nano droplet form, designed for rapid improvement of Vitamin D levels. The sugar-free, ready-to-drink formulation makes it a convenient high-strength option for correcting Vitamin D deficiency.
Key Features
- Each 5 ml contains Cholecalciferol IP (in Nano Droplet form) 60,000 IU
- High-strength formula for rapid improvement of Vitamin D levels
- Sugar-free, ready-to-drink oral solution
- Nano droplet technology intended to support efficient absorption
- Supports bone, muscle and overall calcium metabolism
Key Ingredients
- Cholecalciferol IP (in Nano Droplet form) 60,000 IU per 5 ml
- Flavoured syrup base q.s.
- Colour: Ponceau 4R
Uses
Recalmin D3 Oral Solution is used for the rapid correction of Vitamin D3 deficiency in individuals who require a high-strength, sugar-free supplementation option. Cholecalciferol supports the absorption of calcium and phosphorus, contributing to the maintenance of healthy bones, muscles and immune function, and is particularly suited to periodic high-dose supplementation as advised by a physician.
Directions for Use
Dosage: as directed by the physician. This is a high-strength formulation typically used as a single periodic dose; shake well before use and follow your doctor’s prescribed schedule for supervised supplementation.
Precautions
- Do not take more frequently than advised, as this is a high-strength formulation
- Consult your doctor before use if pregnant, breastfeeding, or if you have kidney disease or hypercalcaemia
- Inform your doctor of any other Vitamin D or calcium supplements you are taking
- Store in a cool, dry place away from direct sunlight
- Keep out of reach of children
Legal Disclaimer: The product is guaranteed to be 100% genuine. Product images are for illustrative purposes only.













Reviews
There are no reviews yet.